SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 13, 2024
– Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 –
– Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory AML After Venetoclax Failure to be Presented at the Upcoming American Society of Hematology (ASH) Annual Meeting in December –
Read more at globenewswire.com
